Schambelan M, Mulligan K, Grunfeld C, Daar E, Lamarca A, Breitmeyer J; National Conference on Human Retroviruses and Related Infections.
Program Abstr Second Natl Conf Hum Retrovir Relat Infect Natl Conf Hum Retrovir Relat Infect 2nd 1995 Wash DC. 1995 Jan 29-Feb 2; 170.
San Francisco, CA.
In patients with HIV-associated wasting, nutritional therapies can increase weight but fail to consistently increase LBM. In view of our previous demonstration that short-term treatment with rhGH caused weight gain, nitrogen retention, and increased lipid oxidation in HIV+ patients with wasting (JCEM, 1993), we designed a multicenter, double-blind, placebo-controlled, phase III trial to evaluate the effects of chronic rhGH treatment on body composition and functional performance. A total of 178 HIV+ patients with weight loss averaging 14% received either mammalian cell-derived rhGH (Serono Laboratories, Inc.), 0.1 mg/kg per day (N=90), or placebo (N=88) for 12 weeks. Treatment with rhGH caused a significant and sustained increase in weight (+1.6+/-0.5 kg) and an even greater increase in LBM (+3.0+/-0.4 kg), accompanied by a significant decrease in fat mass (-1.7+/-0.2 kg) as determined by DEXA. In contrast, weight and body composition in the placebo group were not significantly different from baseline. Treadmill work performance increased significantly with rhGH, but not with placebo. Changes in treadmill work performance correlated directly with changes in LBM (p=0.0007), as did quality of life measures that reflected physical activity. Plasma HIV RNA levels did not change significantly in either group nor were there any significant differences in deaths, dropouts, or AIDS-related conditions. Complaints possibly related to rhGH (joint stiffness, puffiness, and paresthesias) were usually mild and responded to dose reduction. The sustained increase in LBM and increased functional performance make rhGH a unique therapy in patients with HIV-associated wasting.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Body Composition
- Body Weight
- HIV Infections
- HIV Seropositivity
- Human Growth Hormone
- Humans
- Patient Dropouts
- Placebos
- Weight Gain
- Weight Loss
Other ID:
UI: 102213598
From Meeting Abstracts